证券代码：301206 证券简称：三元生物 公告编号：2023-039 山东三元生物科技股份有限公司 关于首次公开发行前已发行的部分股份解除限售并上市 流通的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意山东三元生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】4073 号）同意注册，公司公开发 行人民币普通股（A 股）33,721,000 股，并于 2022 年 2 月 10 日在深圳证券交易 所创业板上市交易。首次公开发行股票完成后，公司总股本由 101,162,800 股变 更为 134,883,800 股，其中有限售条件流通股为 102,902,271 股，占发行后总股本 的比例 76.29%，无限售条件流通股为 31,981,529 股，占发行后总股本的比例为 23.71%。 1 / 5 （二）上市后股份变动情况 特别提示： 1、本次上市流通的限售股为山东三元生物科技股份有限公司（以下简称"公 司"或"三元生物"）首次公开发行前已发行的股份。 2、本次解除限售股 ...

证券代码：301206 证券简称：三元生物 山东三元生物科技股份有限公司 2022 年度业绩说明会投资者关系活动记录表 编号：2023-002 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 采用网络远程方式进行，面向全体投资者 时间 2023 年 5 月 12 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 主持人：三元生物 董事长、代董秘：聂在建 公司接待人员 总经理：程保华 姓名 财务总监：于俊玲 独立董事：赵春海 保荐代表人：陆丹君 公司于2023年5月12日(星期五)下午15:00-17:00，在互动易平台-云 访谈栏目（ http://irm.cninfo.com.cn）举办了2022年度业绩说明会，并就 投资者在本次说明会中提出的相关问题进行了回复，主要内容如下: 投资者关系活动 主要内容介绍 1、元气森林开始没有采购三元生物赤藓糖醇具体时间是哪年哪 月？ 答：尊敬的投资者，您 ...

Financial Performance - The company's operating revenue for 2022 was ¥674,905,595.63, a decrease of 59.71% compared to ¥1,675,320,034.94 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥163,686,641.34, down 69.43% from ¥535,415,008.89 in the previous year[27]. - The cash flow from operating activities for 2022 was ¥84,264,654.04, representing an 86.88% decline from ¥642,075,356.24 in 2021[27]. - Basic earnings per share for 2022 were ¥0.82, a decrease of 76.77% compared to ¥3.53 in 2021[27]. - The company reported a quarterly revenue of ¥272,598,107.02 in Q1 2022, which decreased to ¥111,541,943.95 in Q4 2022[29]. - The net profit attributable to shareholders in Q4 2022 was ¥12,530,699.56, significantly lower than ¥62,765,994.16 in Q1 2022[29]. - The company experienced a significant decline in net profit margins, with a weighted average return on equity of 3.80% in 2022, down from 68.85% in 2021[27]. - The gross profit margin for erythritol products dropped to 10.50% in 2022 from 41.56% in 2021, reflecting a significant decline of 31.06%[57]. - The revenue from the food additive industry was CNY 655.82 million, accounting for 97.17% of total revenue, with a year-on-year decrease of 60.05%[81]. - The company's sales volume in the food additive industry decreased by 47.37% year-on-year, while production volume dropped by 44.08% due to intensified market competition and reduced orders from downstream customers[84]. Market Conditions - The sales revenue of the company's products declined due to economic downturn and weak consumer demand, particularly in the downstream beverage and dining sectors[4]. - The market price of erythritol significantly decreased, compressing the profit margins for industry players due to increased supply from new capacities and expansions by existing companies[4]. - The functional sugar industry, particularly erythritol, faced increased competition in 2022, leading to a supply surplus and a significant drop in prices, impacting profitability[43]. - The overall demand for functional sugars is expected to grow due to increasing consumer awareness of health and nutrition[45]. - The company operates in the functional sugar sector, focusing on erythritol production, which is expected to benefit from the growing health-conscious consumer trend[45]. Investment and R&D - The company invested in a wholly-owned R&D subsidiary to enhance its core technology competitiveness and expand its product range, including new products like stevia and hyaluronic acid[78]. - The company established a wholly-owned R&D subsidiary focused on high-end applications in synthetic biology, collaborating with multiple research institutions[71]. - The company aims to achieve a fermentation reaction cycle of no more than 24 hours and a yield of no less than 95% in glucose acid production[97]. - The company is developing a high-yield strain of yeast for erythritol production, targeting a yield of at least 50% using glucose as the substrate[97]. - The company has completed the development of alulose preparation technology, achieving a purity of over 95%[96]. Production and Supply Chain - The company benefits from a stable supply of raw materials, particularly starch derived from corn, which is abundant in its operational region[46]. - The company employs a "production based on orders" procurement model, maintaining a short inventory cycle for main raw materials and a longer cycle for auxiliary materials[51]. - The production model is customer order-oriented, ensuring timely delivery based on customer specifications and maintaining appropriate finished goods inventory levels[52]. - The company has improved the purity of erythritol extracted from mother liquor from below 50% to over 80% through innovative extraction techniques[68]. - Automation improvements have increased temperature control precision to 0.1°C, compared to the traditional manual control range of 3-5°C[69]. Strategic Initiatives - The company plans to launch a new small packaging brand "Yuan Sheng Tian" to expand its market reach from B2B to B2C, enhancing brand awareness and market influence[54]. - The company is focusing on expanding its retail presence by acquiring a 20% stake in PeiXue Biotechnology to enhance its market influence[79]. - The company aims to maintain its market leadership in erythritol while developing competitive functional sugars and expanding into specialized food, cosmetics, and drug delivery systems, driven by consumer demand for green and healthy products[129]. - The company plans to enhance its R&D capabilities by collaborating with leading food fermentation research institutions to improve product innovation and reduce reliance on a single product[131]. - The company is actively expanding its customer base by targeting small and medium enterprises to reduce reliance on major clients[140]. Governance and Compliance - The company maintains independent operations with complete control over its assets, personnel, finance, and business, ensuring no violations by the controlling shareholder[155]. - The company has established a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status[150]. - The company adheres to strict internal audit procedures, enhancing governance and ensuring the achievement of operational goals[154]. - The company has independent financial accounting systems and decision-making capabilities, complying with accounting standards[157]. - The company has a transparent information disclosure system, ensuring fair access to information for all investors[152]. Shareholder and Dividend Information - The profit distribution plan approved by the board is to distribute a cash dividend of 7 RMB (including tax) for every 10 shares, based on a total of 202,325,700 shares[6]. - The total distributable profit for shareholders was CNY 833,753,971.65, which is the lower of the consolidated and parent company reports[198]. - The cash dividend represents 100% of the total profit distribution amount[195]. - The company strictly follows its profit distribution policy, ensuring clarity and compliance with relevant regulations during the dividend distribution process[193]. - The company distributed a cash dividend of 10.00 yuan per 10 shares, totaling 134,883,800.00 yuan, and increased its share capital by 67,441,900 shares through a capital reserve conversion[192].

Financial Performance - The company's revenue for Q1 2023 was ¥116,276,458.04, a decrease of 57.35% compared to ¥272,598,107.02 in the same period last year[4] - Net profit attributable to shareholders was ¥7,808,194.59, down 87.56% from ¥62,765,994.16 year-on-year[4] - Basic and diluted earnings per share fell by 92.16%, from ¥0.51 to ¥0.04[4] - The total operating revenue for Q1 2023 was ¥116,276,458.04, a decrease of 57.3% compared to ¥272,598,107.02 in the same period last year[25] - The net profit for Q1 2023 was ¥7,808,194.59, a decline of 87.5% compared to ¥62,765,994.16 in Q1 2022[27] Cash Flow - The net cash flow from operating activities decreased by 87.17%, from ¥20,443,976.73 to ¥2,622,930.65[4] - The net cash flow from operating activities for the first quarter was ¥2,622,930.65, a decrease of 87.2% compared to ¥20,443,976.73 in the previous period[31] - Total cash inflow from operating activities was ¥143,143,501.00, down from ¥312,922,891.80 in the previous period[30] - Cash received from sales of goods and services was ¥125,411,624.65, a decline from ¥285,616,286.62 in the previous period[30] - The ending balance of cash and cash equivalents was ¥142,378,891.60, down from ¥267,134,010.23 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,858,759,156.00, a slight decrease of 0.23% from the previous year[4] - The total liabilities for Q1 2023 were ¥230,174,915.00, a decrease from ¥249,143,294.88 in the same period last year[24] - The company's long-term equity investments amounted to ¥59,706,991.87, a slight decrease from ¥60,156,008.48 in the previous year[24] Income and Expenses - The total operating costs for Q1 2023 were ¥135,685,668.54, down 37.1% from ¥215,835,919.52 in Q1 2022[25] - Research and development expenses for Q1 2023 were ¥11,788,523.18, an increase of 15.4% compared to ¥10,219,983.55 in Q1 2022[25] - Other income increased by 1,413.01%, mainly due to government subsidies received during the reporting period[8] - The company reported a significant increase in other income to ¥506,858.66 from ¥33,500.01 in the previous year[27] Shareholder Information - The total number of shares held by major shareholders includes 12,852,000 shares by Liu Xi'an and 5,399,970 shares by Shandong Kexin Venture Capital Co., Ltd[11] - The company reported a total of 92,946,000 restricted shares held by Nie Zaijian, with the release date set for August 10, 2025[13] - The company has 24,780,000 shares released from restrictions as of February 10, 2023, indicating a significant liquidity event for shareholders[14] - The total number of shares held by the top 10 unrestricted shareholders includes 2,681,475 shares by Wang Shen and 2,653,995 shares by Wang Meihua[11] Fund Management - The company plans to use RMB 790 million of the raised funds to permanently supplement its working capital starting from March 2, 2023[16] - The company approved the use of up to RMB 2.4 billion of temporarily idle raised funds for cash management, effective for 12 months from the approval date[17] - The company intends to use up to RMB 2.2 billion of temporarily idle self-owned funds for cash management, also effective for 12 months from the approval date[18] Investment Activities - Total cash inflow from investment activities was ¥10,416,708.33, significantly up from ¥477,900.00 in the previous period[31] - The net cash flow from investment activities was -¥328,183,999.71, compared to -¥3,562,704,045.45 in the previous period, indicating a reduction in cash outflow[31] Share Reduction Plans - The company’s major shareholder, Shandong Luxin Qisheng Investment Management Co., plans to reduce its holdings by up to 12.14 million shares, representing 6% of the total share capital[20] - The chairman of the supervisory board, Cui Zhenqian, completed a share reduction plan, selling up to 170,625 shares, which is 0.0843% of the total share capital[19] Other Information - The company did not engage in any financing activities during the reporting period, resulting in a 100% decrease in cash flow from financing activities[8] - The company did not report any new product developments or market expansions during this quarter[32]

证券代码：301206 证券简称：三元生物 公告编号：2023-031 2023 年 4 月 27 日 特此公告。 山东三元生物科技股份有限公司 山东三元生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 董事会 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日在 巨潮咨询网（www.cninfo.com.cn）上披露了公司《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者进一步了解公司生产经营、财务状况、战 略规划等情况，公司定于 2023 年 5 月 12 日（星期五）下午 15:00-17:00 在深圳 证券交易所"互动易"平台举行 2022 年度网上业绩说明会，就投资者关心的问 题进行交流。本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券 交易所"互动易"平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次 业绩说明会。 出席本次业绩说明会人员有：董事长、代行董事会秘书聂在建先生，总经理 程保华先 ...

证券代码：301206 证券简称：三元生物 三元生物上市公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-------------------|------------------------------------------------|----------------------------------------------------------------| | | √特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 □电话会议 | | | | □其他： （请文字说明其他活动内容） | | | 参与单位名称 | 华夏基金及其邀请人员 6 | 人；南方基金及其邀请人员 5 人 | | 及人员姓名 | | | | 时间 | 2022 年 4 月 29 日 | | | 地点 | 网络会议 | | | 公司接待人员 姓名 | 代行董事会秘书聂在建先生、证券部工作人员 | | | | Q&A | 交流问题纪要（口头交流内容表述可能存在误差，如与正式公告内 ...

编号：2022-008 1 / 3 证券代码：301206 证券简称：三元生物 山东三元生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动类 别 | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 √ | 电话会议 | | | □ 其他： | （请文字说明其他活动内容） | | 参与单位名称 | | 华商基金郭鹏；中金宗旭豪、钱凌霄、张毓 | | 及人员姓名 | | | | 时间 | 2022 年 9 月 20 日 | 08:30-09:30 | | 地点 | 网络会 ...

证券代码：301206 证券简称：三元生物 编号：2022-007 山东三元生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √ 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类 | □新闻发布会 | □路演活动 | | 别 | □现场参观 √ | 电话会议 | | | □其他： | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 摩根高云；中金宗旭豪、候一林、夏雪、舒嫣然 | | 时间 | 2022 年 8 月 26 日 | 14:30-16:00 | ...

Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company reported total revenue of CNY 563,363,651.68 for the current period, down from CNY 1,305,360,240.59 in the previous period, indicating a decline of approximately 56.7%[26] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in the same period last year[28] - Operating profit for Q3 2022 was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in Q3 2021[28] - The total comprehensive income for Q3 2022 was CNY 151,155,941.78, down from CNY 440,682,536.29 in the same quarter last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, total assets amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[22] - The total liabilities decreased to CNY 189,942,474.74 from CNY 588,828,870.18, a reduction of approximately 67.8%[24] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, a decrease of 82.62% year-on-year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] - Cash flow from operating activities generated a net inflow of CNY 90,426,851.62, significantly lower than CNY 520,410,877.71 in the previous year[30] - Investment activities resulted in a net cash outflow of CNY 3,282,248,061.08, compared to a smaller outflow of CNY 330,668,081.12 in the previous year[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, amounting to 92,946,000 shares[14] - The second-largest shareholder, Shandong Luxin Qisheng Investment Management Co., holds 12.25% of the shares, totaling 24,780,000 shares[14] - The company has a total of 154,353,406 restricted shares, with 2,609,206 shares released during the reporting period[17] - The company has no knowledge of any related party relationships among the top ten shareholders[15] - The company has not disclosed any information regarding the participation of the top ten shareholders in margin trading[15] - The company plans to release restricted shares on specific dates, with the earliest being February 10, 2023, for several shareholders[16] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 year-over-year[28] Certification and Auditing - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its customs clearance efficiency internationally[20] - The company changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, reflecting a strategic shift in its auditing needs[19] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, representing a reduction of approximately 76.3%[22] - Inventory levels were reported at CNY 73,203,380.23, down from CNY 112,157,402.58, indicating a decrease of about 34.7%[23] Capital Changes - The company completed a capital increase, raising its total share capital from 134,883,800 shares to 202,325,700 shares, a 49.9% increase[18] Investment Income - Investment income for the first nine months of 2022 was CNY 60,094,512.56, an increase of 85582.95% year-on-year due to interest from bank large-denomination certificates[10] - The company received CNY 850,000,000.00 from investment recoveries during the reporting period[30]